Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

SIMPLE SUMMARY: Cancer is largely caused by genetic alterations such as mutations in a group of genes known as cancer driver genes. Many of the key advances in cancer treatment in recent years have involved blocking these driver genes using a new generation of anti-cancer drugs. Although p53 is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Duffy, Michael J., Tang, Minhong, Rajaram, Subhasree, O’Grady, Shane, Crown, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496879/
https://www.ncbi.nlm.nih.gov/pubmed/36139658
http://dx.doi.org/10.3390/cancers14184499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496879/
https://www.ncbi.nlm.nih.gov/pubmed/36139658
http://dx.doi.org/10.3390/cancers14184499

Ejemplares similares